Physician profile
Adrian Deme
NPI 1700882107
$16,200.15
in general payments reported to CMS, 2019-2025
47 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $1,966 · 2021: $2,082 · 2022: $2,445 · 2023: $2,679 · 2024: $2,548 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,424 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,423.88 |
| Education | $140.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,900.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,607.04 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $1,482.52 | 2020-2025 | Vraylar, Ubrelvy, Creon |
| Lilly USA, LLC | $1,310.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,137.12 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,096.96 | 2019-2025 | |
| Novo Nordisk INC | $1,016.13 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $956.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $621.92 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $489.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $486.57 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $486.31 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $484.49 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $375.07 | 2019-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $215.65 | 2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Deme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.